Paper41007845
Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential.
Liu G and 5 others. Biomedicines, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential. Papers, record 41007845. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41007845
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Reimagining Oncologic Drugs in Atherosclerosis: Emerging Mechanisms and Therapeutic Potential.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References174
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 40214442 | The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis. | Cells | 2025 | https://conductscience.org/library/papers/40214442 | PubMed |
| 2 | 36040835 | Cardiovascular complications of immune checkpoint inhibitors for cancer. | Eur Heart J | 2022 | https://conductscience.org/library/papers/36040835 | PubMed |
| 3 | 16037567 | Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. | Arterioscler Thromb Vasc Biol | 2005 | https://conductscience.org/library/papers/16037567 | PubMed |
| 4 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 5 | 33277608 | Engineering precision nanoparticles for drug delivery. | Nat Rev Drug Discov | 2021 | https://conductscience.org/library/papers/33277608 | PubMed |
| 6 | 37644871 | Comparison of Long-Term Outcomes Between Intravascular Ultrasound-, Optical Coherence Tomography- and Angiography-Guided Stent Implantation: A Meta-Analysis. | Angiology | 2024 | https://conductscience.org/library/papers/37644871 | PubMed |
| 7 | 23598172 | Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. | Lancet Oncol | 2013 | https://conductscience.org/library/papers/23598172 | PubMed |
| 8 | 16160601 | Rapamycin attenuates atherosclerotic plaque progression in apolipoprotein E knockout mice: inhibitory effect on monocyte chemotaxis. | J Cardiovasc Pharmacol | 2005 | https://conductscience.org/library/papers/16160601 | PubMed |
| 9 | 23964934 | Pazopanib versus sunitinib in metastatic renal-cell carcinoma. | N Engl J Med | 2013 | https://conductscience.org/library/papers/23964934 | PubMed |
| 10 | 27941169 | Nilotinib attenuates endothelial dysfunction and liver damage in high-cholesterol-fed rabbits. | Hum Exp Toxicol | 2017 | https://conductscience.org/library/papers/27941169 | PubMed |
| 11 | 26371140 | Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia. | J Clin Oncol | 2015 | https://conductscience.org/library/papers/26371140 | PubMed |
| 12 | 29079346 | Axitinib attenuates intraplaque angiogenesis, haemorrhages and plaque destabilization in mice. | Vascul Pharmacol | 2018 | https://conductscience.org/library/papers/29079346 | PubMed |
| 13 | 30827782 | Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. | Lancet | 2019 | https://conductscience.org/library/papers/30827782 | PubMed |
| 14 | 22451584 | Pulmonary arterial hypertension in patients treated by dasatinib. | Circulation | 2012 | https://conductscience.org/library/papers/22451584 | PubMed |
| 15 | 25652038 | Rapamycin-mediated mTORC2 inhibition is determined by the relative expression of FK506-binding proteins. | Aging Cell | 2015 | https://conductscience.org/library/papers/25652038 | PubMed |
| 16 | 30380386 | CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30380386 | PubMed |
| 17 | 38763321 | Altered cancer metabolism and implications for next-generation CAR T-cell therapies. | Pharmacol Ther | 2024 | https://conductscience.org/library/papers/38763321 | PubMed |
| 18 | 34286881 | Reactive oxygen species in cancer: Current findings and future directions. | Cancer Sci | 2021 | https://conductscience.org/library/papers/34286881 | PubMed |
| 19 | 36744254 | Natural compounds from botanical drugs targeting mTOR signaling pathway as promising therapeutics for atherosclerosis: A review. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/36744254 | PubMed |
| 20 | 29933080 | Pharmacological strategies to inhibit intra-plaque angiogenesis in atherosclerosis. | Vascul Pharmacol | 2019 | https://conductscience.org/library/papers/29933080 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41007845
GET https://conductscience.org/api/papers/v1/41007845/references?page=2